Targeting TTR amyloidosis at its source. Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $64M
Founded date: 2013
Investors 5
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Hercules C... | htgc.com |
| - | RA Capital... | racap.com |
| - | MBC BioLab... | mbcbiolabs... |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.04.2018 | Series B | $64M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 15.10.2019 | BridgeBio terminates effort to acquire remainder of Eidos Th... | Eidos trades publicly on the Nasdaq, and its shares fell 6.5 percent Monday morning following the ne... | medcitynew... |
| 23.01.2019 | BridgeBio Pharma raises $299.2M in financing round | The company plans to use the money support and expand upon existing research and development program... | medcitynew... |
| 05.04.2018 | Eidos Therapeutics Closes $64M Series B Financing | Eidos Therapeutics, Inc., a San Francisco, CA-based clinical stage biopharmaceutical company develop... | finsmes.co... |
| - | BridgeBio Pharma raises $299.2M in financing round | A company focused on developing genetically targeted drugs discovered by academia and then building ... | medcitynew... |
| - | BridgeBio terminates effort to acquire remainder of Eidos Th... | A firm that helps launch biomedical research into new companies has called off a bid to acquire one ... | medcitynew... |